Dapagliflozin in Patients With Ulcerative Colitis

StatusCompleted
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Final enrollment: 60 participants (planned 50)
    • Primary completion date changed from estimate of Aug 20, 2027 to Aug 20, 2026
    • Eligibility criteria expanded, about 11 words
    • Site details revised
    • Study title shortened, about 7 words
  2. Primary completion date: Aug 20, 2025 to Aug 20, 2027v4
  3. Primary completion date: Aug 20, 2024 to Aug 20, 2025v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mostafa Bahaa
14 trials monitored
See 1 trial at risk
The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.
Trial Details
NCT Number NCT05986136
Lead Sponsor Mostafa Bahaa
Conditions
(from sponsor)		 Inflammatory Bowel Diseases
Related terms Inflammatory Bowel Diseases
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov